Bayer AG Nubeqa Investor Webinar Transcript
Good afternoon, and good morning, everybody. It's a great pleasure to be with you today, and I welcome you to our next investor webinar of our Pharma division. With this second webinar this week, we continue our series of events to keep you appraised of key developments and milestones across the group. Following our webinar on KERENDIA in November last year, we today focus on our second promising launch asset Nubeqa or darolutamide.
Last night, detailed study data of ARASENS, our Phase III trial that examine the efficacy and safety of darolutamide to treat prostate cancer in a late stage of the disease, have been presented at the ASCO GU for the first time. We will put these data into perspective with existing treatment options and discuss how the broadened clinical profile of darolutamide can change the treatment paradigm in prostate cancer in the future. Finally, we will give an update on our further development program and the commercial potential of darolutamide.
I'm delighted that the coordinating
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
